Preliminary analysis showed the 2025-2026 formula of mNEXSPIKE generated greater than a 16-fold increase in LP.8.1-neutralizing antibodies across age groups Both of Moderna’s COVID-19 vaccines for the ...
Moderna, Inc. (NASDAQ:MRNA) ranks among the best biotech stocks to buy. Following solid trial results for Moderna, Inc.
Moderna (MRNA) announced preliminary immunogenicity data for the 2025-2026 formula of mNEXSPIKE, which targets the LP.8.1 variant of SARS-CoV-2 to ...
US mRNA specialist Moderna today announced positive preliminary immunogenicity data for the 2025-2026 formula of mNEXSPIKE ...
Moderna said on Tuesday its updated COVID-19 vaccine formulation elicited a strong immune response in all adults aged 65 and ...
Moderna Inc. (NASDAQ:MRNA) on Tuesday released preliminary immunogenicity data for the 2025-2026 formula of mNEXSPIKE ...
Moderna said on Tuesday its updated COVID-19 vaccine formulation elicited a strong immune response in all adults aged 65 and older, as well as in individuals aged 12 to 64 with at least one underlying ...
US health technology body ICER will review the comparative clinical effectiveness and value of four COVID-19 vaccines: Pfizer ...
Moderna (MRNA) stock is in focus as its updated mNEXSPIKE COVID vaccine boosts antibodies 15-fold on average against the new ...
Asianet Newsable on MSN
Moderna Says Updated mNEXSPIKE Covid Shot Demonstrated Robust Immune Response In Study
Moderna (MRNA) said on Tuesday that its 2025-2026 formula of mNEXSPIKE demonstrated a strong immune response in recipients in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback